Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
List view / Grid view
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
6 October 2015 | By Victoria White
The new building is designed to support the Company’s continuing growth of its research and development operation and is scheduled for delivery in late 2016...